MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Regulation FD Disclosure

On December 13, 2017, MabVax Therapeutics Holdings, Inc. (the “Company”) issued a press release that reported the Company had completedenrollment and dosing in the initial cohort of the MVT-1075 radioimmunotherapy phase 1 trial for the treatment of pancreatic, colon and lung cancers. The press release is attached hereto as Exhibit 99.1.

The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

(d)Exhibits.

The exhibit listed in the following Exhibit Index is furnished with this Current Report on Form 8-K.

MABVAX THERAPEUTICS HOLDINGS, INC. ExhibitEX-99.1 2 ex99-1.htm PRESS RELEASE ex99-1   Exhibit 99.1   MabVax Therapeutics Announces Completion of Enrollment and Dosing in Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic,…To view the full exhibit click here